Loical Soft Capsule (Calcitriol)

Adult dose

○ For patients before dialysis treatment: The initial recommended dose of calcitriol is 0.25 µg per day, which may be increased to 0.5 µg per day if necessary. ○ Renal osteodystrophy (dialysis patients): The initial daily dose is 0.25 µg, and patients with serum calcium levels within normal range or slightly decreased should receive 0.25 µg every other day. If there is insufficient response in biochemical test results and clinical symptoms, increase the dose by 0.25 µg every 2-4 weeks.

Child dose

○ For patients before dialysis treatment: For children aged 36 months and older, the initial recommended dose of calcitriol is 0.25 µg per day, which may be increased to 0.5 µg per day if necessary. ○ 36 months

This drug should not be used in patients with diseases associated with hypercalcemia or hypercalciuria. Also, it should not be administered to patients with allergies to this drug or similar drugs, those with symptoms of vitamin D toxicity, and patients with primary hyperparathyroidism. It should be used cautiously in pregnant women or those who may become pregnant, nursing mothers, children under 36 months, children receiving hemodialysis, patients with a history of kidney stones, and sarcoidosis patients. This drug, being an active metabolite of vitamin D, can cause symptoms similar to hypercalcemia if overdosed, which can lead to adverse reactions from various systems including digestive, neurological, circulatory, sensory, skeletal, respiratory, urinary, liver, kidney, skin, and eyes. Adequate calcium intake is essential during treatment, and one should be careful not to exceed the recommended daily intake of calcium. To prevent overdose, serum calcium levels should be routinely checked and dose adjusted to maintain normal ranges. Particularly, if symptoms of hypercalcemia appear, the medication should be discontinued immediately, and consultation with healthcare providers is recommended. This drug may interact with other vitamin D preparations or calcium supplements, certain diuretics, digitalis, etc., therefore caution is required when combined. Pregnant or nursing women should use this drug cautiously as it may affect the fetus or newborn, under the physician’s judgment. In children or the elderly, adjustments in dosage and closer monitoring of serum calcium levels are warranted due to potential differences in bodily function. In case of overdose, emergency treatments such as inducing vomiting or gastric lavage are needed, and appropriate treatment for symptoms due to hypercalcemia should be carried out. Care should be taken when driving or operating machinery while on this medication, as overdose may impair these abilities. For storage, keep it out of reach of children, avoid light and moisture, and store it below 25 degrees Celsius. Medications should be kept in their original container to prevent quality degradation or misuse.

Serious side effects

Hives, severe swelling (edema), high fever, rash, difficulty breathing, yellowing of the skin (jaundice), severe allergic reaction, severe skin reaction, respiratory issues, liver problems (jaundice), serious neurological symptoms, significant reduction in urine output, severe edema or urinary abnormalities, hypercalcemia, hypercalciuria, hyperphosphatemia, arrhythmia, metastatic calcification of the myocardium, nephrocalcinosis, systemic vascular calcification, renal failure, confusion of consciousness.

Mild side effects

• Nausea
• diarrhea
• loss of appetite
• constipation
• vomiting
• gastric discomfort
• abdominal pain
• thirst
• abdominal cramping
• ileus

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, ideally between 1 to 30 degrees Celsius at room temperature. This storage method helps to maintain the effectiveness of the medication and prevents degradation.

Appearance

Oval soft capsules that contain a colorless or transparent liquid, with a milky white color.

Package unit

60 capsules/PTP, 100 capsules/bottle